Imap (Fluspirilene)

Fluspirilene works by blocking dopamine D2 receptors in the brain, decreasing dopaminergic activity in pathways that are over‑active in schizophrenia, which leads to symptom improvement.

The dosage of Imap is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Specific dosing regimens are not disclosed publicly.

Safety data for fluspirilene in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Imap product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Imap (fluspirilene) is a typical, first‑generation antipsychotic that primarily blocks dopamine D2 receptors, whereas many newer agents are atypical antipsychotics with broader receptor profiles and potentially lower risk of extrapyramidal side effects.

Imap should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintain the original packaging to preserve stability.

Imap is supplied as an intramuscular injection. It is administered by a qualified healthcare professional into a suitable muscle, typically following aseptic technique and according to the prescriber’s instructions.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, agranulocytosis, severe hypotension, and cardiac arrhythmias. Patients should be monitored closely for any signs of these conditions.

Imap is contraindicated in individuals with known hypersensitivity to fluspirilene or any of its excipients, and it should be used with caution in patients with severe cardiovascular disease, Parkinson’s disease, or a history of neuroleptic malignant syndrome.